Entrada Therapeutics Q3 EPS $1.02 May Not Be Comparable To $(0.74) Estimate, Sales $43.73M May Not Be Comparable To $9.60M Estimate
Portfolio Pulse from Benzinga Newsdesk
Entrada Therapeutics reported Q3 earnings of $1.02 per share, beating the analyst consensus estimate of $(0.74) by 237.84 percent. This is a 227.5 percent increase over losses of $(0.80) per share from the same period last year. The company also reported quarterly sales of $43.73 million, beating the analyst consensus estimate of $9.60 million by 355.57 percent.
November 07, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Entrada Therapeutics reported significantly higher Q3 earnings and sales than expected, which could positively impact the stock.
Entrada Therapeutics reported Q3 earnings and sales that significantly exceeded analyst estimates. This strong performance could increase investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100